Skip to content
Agentic OS
Menu

Intelligence / B2B SaaS / Acquisitions / Impact Biomedical INC.

M&Awas acquired (SEC 8-K)18 Nov 2026

Impact Biomedical INC.

18 Nov 2026: Was acquired (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.

View the source record

Filed
18 Nov 2026
Ticker
IBO
Role
Was acquired
Sector
Pharma and biotech
Sic
2834
Items
2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
Summary
Pursuant to the Merger Agreement, on November 17, 2026 (the " Closing Date "), (i) Merger Sub merged with and into the Company (the " Merger "), with the Company continuing as the surviving corporation and as a wholly-owned subsidiary of PubCo (the " Surviving Corporation "), and (ii) simultaneously with or immediately
Location
West Henrietta, NY
State
New York
Country
United States
SEC CIK
1834105
Reference
0001493152-26-053017
What this signal means

Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.

  1. Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
  2. 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS

Find the decision makers at Impact Biomedical INC.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.

Start free

More in Was acquired

Acquisitions

See all

Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.